Shanghai Auson Pharmaceuticals Co., Ltd.

Main purpose: Using the sildenafil citrate dispersible tablets certified by Shanghai Aoquan Biopharmaceutical Technology Co., Ltd. as the test preparation and the sildenafil citrate tablets (trade name: REVATIO®) certified by Pfizer Europe MA EEIG as the reference preparation, the pharmacokinetic behavior in healthy subjects was compared according to the relevant provisions of the bioequivalence test, and the bioequivalence of the two preparations in the fasting/postprandial state was evaluated. Secondary purpose: 1. Evaluate the safety of the test preparation and the reference preparation after a single oral administration of the test preparation and the reference preparation in healthy subjects on an empty stomach/postprandial basis. Collect sensory evaluation questionnaires within 15 minutes after taking the sildenafil citrate dispersible tablets (including taste, flavor, and aftertaste after administration).

Main purpose: The apixaban dispersible tablets provided by Shanghai Aoquan Biopharmaceutical Technology Co., Ltd. were used as the test preparation (2.5 mg/tablet), and the apixaban tablets (Eliquis®, 2.5 mg/tablet) produced by Bristol-Myers Squibb Manufacturing Company were used as the reference preparation to compare the pharmacokinetic (PK) behavior of apixaban dispersible tablets and apixaban tablets in healthy Chinese subjects, and to evaluate the bioequivalence of the two preparations after fasting and postprandial oral administration. Secondary purpose: 1. To evaluate the safety of single oral administration of apixaban dispersible tablets and apixaban tablets in healthy Chinese subjects after fasting and postprandial administration. 2. To collect sensory evaluation questionnaires (including taste, flavor, and aftertaste after taking the medicine) within 15 minutes after taking the apixaban dispersible tablets.